Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today
1.9.2020 18:30:00 EEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005819/en/
The publication marks a clear consensus on allergen immunotherapy (AIT). It was co-authored by 49 world-renowned allergy specialists from 40 countries and coordinated by Professor Giorgio Walter Canonica, Personalised Medicine, Asthma and Allergy, Humanitas University and Research (Milano, Italy) and Professor Cristoforo Incorvaia, Cardiac/Pulmonary Rehabilitation, ASST Pini/CTO, (Milano, Italy), with an unrestricted grant from Stallergenes Greer.
The article demonstrates that there is very strong evidence to show that AIT achieves its primary therapeutic goals in patients with respiratory allergies1,2 by reducing the frequency and intensity of symptoms, the use of rescue medications, and improving quality of life for people with allergies.
Personalised medicine is improving the effectiveness and precision of allergy diagnosis and consequently increasing the performance and treatment outcome of AIT.
“This landmark publication, which is fully aligned with Stallergenes Greer’s commitment, highlights the unique role of AIT in allergy treatment encompassing the prediction of a successful treatment, the potential prevention or progression of an allergic disease, and the possibility of providing such advances at affordable costs,” states Amer Jaber, EVP Operations Europe and President of Stallergenes SAS, who heads Stallergenes Greer's R&D.
AIT: a medical model of personalised healthcare
The article outlines that personalised allergy care is valuable and may also be preventive by focusing on quality of life, predictive by allowing treatment to be adjusted to the individual’s response and participative by empowering the patient.
AIT is consistent with the three major needs to be met in personalised medicine:
- the identification of the molecular mechanism of the disease,
- the availability of diagnostic tools to recognise this mechanism, and
- the availability of a treatment capable of blocking the mechanism3,4.
AIT delivers customised healthcare, with medical decisions, practices, and/or products tailored to the individual patient5.
Leveraging precision medicine for personalised allergy care
This tailor-made approach to diagnosis, decision-making, product choice and treatment schedules may enhance effectiveness, minimise adverse events, improve quality of life and reduce the socio-economic impact of allergies 6,7,8,9.
Stallergenes Greer’s purpose “Enabling precision medicine to improve life for people with allergies” is in line with the statements set out in the article. Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to maximise treatment outcomes for patients with allergies.
Read the full article here: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14575
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at: https://www.stallergenesgreer.com/
1 Roberts G, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73(4):765-798.
2 Demoly P, et al. The Potential Role of Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):640-648.
3 Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010: 22; 363(4):301-4.
4 Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy. 2015: 8;13:24.
5
Canonica GW, et al. Allergen Immunotherapy (AIT): A prototype of precision medicine. World Allergy Organ J. 2015;8 (1), 31 2015.
6 Gueguen C, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016; 137:545-558.
7 Caillot N, et al. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy. J Allergy Clin Immunol. 2017;140; 759-770.
8 Gueguen C, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. Allergy. 2019; 74:2223-2226.
9 Luce S, et al. Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy. Allergy. 2020; 75:1513-1516.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005819/en/
Contact information
Communications
Catherine Kress
Tel: +33 01 55 59 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel18.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today announced a four-year global partnership with Formula 1, becoming the Official Health & Fitness Wearable Partner of Formula 1 and the first consumer wearable approved by the FIA for in-race use. Beginning in 2027, the partnership will bring continuous physiological monitoring to one of the world's most demanding sports, helping drivers and teams better understand how their bodies respond to the demands of competition while giving fans a new perspective on the human performance behind the wheel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118567291/en/ WHOOP and Formula 1 Partner to Reveal the Human Performance Behind the Wheel WHOOP is working to bring fans closer to the action than ever before, with Formula 1 integrating real-time physiological data from participating drivers into its broadcast across the season through WHOOP Live. For the first time, fans will be able to see
Xsolla Connects Players, Brands, and Video Game Audiences Through Rewarded Engagement18.11.2026 17:16:00 EET | Press release
Xsolla (USA), Inc., a global commerce company, announces Xsolla Ads, a rewarded marketing solution connecting brands with game audiences through quests players choose to take part in. Studios generate revenue beyond player purchases while brands drive measurable engagement, acquisition, and purchases. Players choose which campaigns to participate in and which rewards to receive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117947414/en/ Graphic: Xsolla Players see Xsolla Ads where they already are, including the Xsolla App, game web shops, branded pages on Xsolla, Xsolla Choice surveys, and an opt-in Offerwall. Quests are triggered by game events, such as reaching a new level or season, so studios connect campaigns to what players already do in their games. Completed quests can unlock in-game currency, digital items, Xsolla Points, and other rewards delivered through Xsolla Backpack, where players store their digital it
Future Health Launches Academy to Translate Life Sciences Advances Into Strategic Action18.11.2026 16:37:00 EET | Press release
Future Health - A Global Initiative by Abu Dhabi has launched the Future Health Academy as part of its year-round programme, designed to build knowledge, connect expertise and create opportunities for collaboration among health and life sciences professionals in Abu Dhabi and internationally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118051527/en/ The Future Health Academy will build knowledge and connect expertise among health and life sciences professionals in Abu Dhabi and internationally. Through practical, science-focused learning, the Academy will create opportunities for local and international professionals across the health and life sciences ecosystem to engage with emerging developments and consider their implications for research, clinical practice, investment and innovation. Drawing on leading local and international expertise, it will support two-way knowledge exchange by bringing global perspectives to
Soracom Launches Physical AI Suite, Bringing Secure Connectivity and Remote Operations to Robots and Autonomous Machines18.11.2026 16:30:00 EET | Press release
Soracom, Inc. (TSE: 147A), a cloud-native IoT platform providing connectivity, cloud integration, and AI services for the Internet of Things, today announced Soracom Physical AI Suite, a set of Soracom platform services combined to connect, protect, and manage physical AI systems such as robots, autonomous mobile machines, and industrial equipment. Soracom Physical AI Suite is the company's second suite, following Soracom Automotive Suite announced in July 2026. Each suite brings together Soracom platform services commonly used for a particular type of deployment, organizing them into a single system. A team starting a new deployment begins from that system instead of selecting and assembling services one at a time. The suite is designed for companies that develop or deploy robots and other physical AI systems and for companies that operate connected equipment in industries including manufacturing, logistics, energy, infrastructure, and building management. A physical AI system extends
Variational Raises $110M Series B at $1.5B Valuation To Scale On-Chain Access To Global Markets18.11.2026 16:23:00 EET | Press release
Variational, a protocol for on-chain derivatives trading, has announced a $110M Series B raise at a $1.5B valuation led by Bain Capital Crypto with support from Dragonfly, HSG, Peak XV, 50T Funds, and more. Since launching in early 2025, the platform has processed $475B+ in trading volume and accumulated $1.3B+ in open interest across 100k+ accounts. More than half of daily volume on the platform is now on traditional markets. The raise will fund the platform’s continued growth, allowing Variational to list hundreds more markets and lift open interest caps that traders increasingly hit. Omni, a trading platform built on Variational, offers leveraged trading on 550+ crypto and traditional markets. Unlike other on-chain trading platforms, Omni aggregates liquidity from both traditional and on-chain markets. This model allowed the platform to launch “swaps” in September 2026, a new instrument that gives on-chain traders access to liquidity from traditional financial institutions. Swaps ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
